University of California San Francisco

Publications

  1. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
    Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L
    Cell Rep Med. 2024 Nov 19; 5(11):101799.; 
    PubMed
  2. Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.
    McCune E, Sharma A, Johnson B, O'Meara T, Theiner S, Campos M, Heditsian D, Brain S, Gilbert JA, Esserman L, Campbell MJ
    mSystems. 2024 Nov 19; 9(11):e0123724.; 
    PubMed
  3. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A
    NPJ Breast Cancer. 2024 Aug 04; 10(1):71.; 
    PubMed
  4. Tumor microenvironmental determinants of high-risk DCIS progression.
    Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, Lee K, Nachmanson D, Officer A, Harismendy O, Stein J, Stein G, Evans M, Weaver D, Yau C, Hirst G, Campbell M, Esserman L
    Res Sq. 2024 May 09.; 
    PubMed
  5. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF
    Cell Rep Med. 2023 12 19; 4(12):101312.; 
    PubMed
  6. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI
    JAMA Netw Open. 2023 12 01; 6(12):e2349646.; 
    PubMed
  7. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM
    Breast Cancer Res. 2023 10 04; 25(1):117.; 
    PubMed
  8. Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards.
    Chung R, Garratt J, Remer EM, Navin P, Blake MA, Taffel MT, Hackett CE, Sharbidre KG, Tu W, Low G, Bara M, Carney BW, Corwin MT, Campbell MJ, Lee JT, Lee CY, Dueber JC, Shehata MA, Caoili EM, Schieda N, Elsayes KM
    Radiographics. 2023 07; 43(7):e220191.; 
    PubMed
  9. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ
    Cancer Res Commun. 2022 12; 2(12):1579-1589.; 
    PubMed
  10. Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19.
    Collins RA, DiGennaro C, Beninato T, Gartland RM, Chaves N, Broekhuis JM, Reddy L, Lee J, Deimiller A, Alterio MM, Campbell MJ, Lee YJ, Khilnani TK, Stewart LA, O'Brien MA, Alvarado MVY, Zheng F, McAneny D, Liou R, McManus C, Dream SY, Wang TS, Yen TW, Alhefdhi A, Finnerty BM, Fahey TJ, Graves CE, Laird AM, Nehs MA, Drake FT, Lee JA, McHenry CR, James BC, Pasieka JL, Kuo JH, Lubitz CC
    Surgery. 2023 Jan; 173(1):93-100.; 
    PubMed
  11. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
    Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ
    NPJ Breast Cancer. 2021 May 25; 7(1):59.; 
    PubMed
  12. Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.
    Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ
    J Mammary Gland Biol Neoplasia. 2020 12; 25(4):417-432.; 
    PubMed
  13. Germline genetic contribution to the immune landscape of cancer.
    Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Galon J, Ziv E, Bedognetti D
    Immunity. 2021 02 09; 54(2):367-386.e8.; 
    PubMed
  14. Adrenal Tumors Found During Staging and Surveillance for Colorectal Cancer: Benign Incidentalomas or Metastatic Disease?
    Yanagisawa M, Malik DG, Loehfelm TW, Fananapazir G, Corwin MT, Campbell MJ
    World J Surg. 2020 07; 44(7):2282-2287.; 
    PubMed
  15. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C
    Breast Cancer Res Treat. 2017 01; 161(1):41-50.; 
    PubMed
  16. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L
    Breast Cancer Res Treat. 2017 01; 161(1):17-28.; 
    PubMed
  17. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ
    PLoS One. 2013; 8(10):e79114.; 
    PubMed
  18. Biology of breast cancer in Nigerian women: a pilot study.
    Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ
    Ann Afr Med. 2012 Jul-Sep; 11(3):169-75.; 
    PubMed
  19. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ
    Ann Surg Oncol. 2012 Nov; 19(12):3979-86.; 
    PubMed
  20. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ
    Breast Cancer Res Treat. 2011 Nov; 130(2):635-44.; 
    PubMed
  21. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ
    Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100.; 
    PubMed
  22. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
    Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ
    Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.; 
    PubMed
  23. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
    Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ
    Breast Cancer Res Treat. 2010 Jan; 119(1):137-44.; 
    PubMed
  24. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID
    J Cell Biochem. 2008 Feb 01; 103(2):624-35.; 
    PubMed
  25. Breast cancer growth prevention by statins.
    Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC
    Cancer Res. 2006 Sep 01; 66(17):8707-14.; 
    PubMed
  26. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM
    Cancer Gene Ther. 2006 Nov; 13(11):1002-10.; 
    PubMed
  27. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.
    Kumar AS, Campbell M, Benz CC, Esserman LJ
    J Clin Oncol. 2006 May 01; 24(13):2127; author reply 2127-8.; 
    PubMed
  28. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
    Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF
    Mol Cancer Ther. 2006 Apr; 5(4):1079-86.; 
    PubMed
  29. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID
    Breast Cancer Res Treat. 2005 Nov; 94(1):37-46.; 
    PubMed
  30. In vitro anticancer activity of twelve Chinese medicinal herbs.
    Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ
    Phytother Res. 2005 Jul; 19(7):649-51.; 
    PubMed
  31. Immune dysfunction and micrometastases in women with breast cancer.
    Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ
    Breast Cancer Res Treat. 2005 May; 91(2):163-71.; 
    PubMed
  32. Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells.
    Kim SW, Chao TH, Xiang R, Lo JF, Campbell MJ, Fearns C, Lee JD
    Cancer Res. 2004 Nov 01; 64(21):7732-9.; 
    PubMed
  33. Reduction of MTT by aqueous herbal extracts in the absence of cells.
    Shoemaker M, Cohen I, Campbell M
    J Ethnopharmacol. 2004 Aug; 93(2-3):381-4.; 
    PubMed
  34. Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro.
    Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D
    Anticancer Res. 2002 Nov-Dec; 22(6C):3843-52.; 
    PubMed
  35. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
    Campbell MJ, Wollish WS, Lobo M, Esserman LJ
    In Vitro Cell Dev Biol Anim. 2002 Jun; 38(6):326-33.; 
    PubMed
  36. Ductal growth is impeded in mammary glands of C-neu transgenic mice.
    Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G
    Oncogene. 2000 Dec 07; 19(52):5982-7.; 
    PubMed
  37. Biological therapies for breast carcinoma: concepts for improvement in survival.
    Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM
    Semin Oncol. 1999 Aug; 26(4 Suppl 12):28-40.; 
    PubMed
  38. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
    Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ
    Cancer Immunol Immunother. 1999 Feb; 47(6):337-42.; 
    PubMed
  39. Clinical trials of idiotype-specific vaccine in B-cell lymphomas.
    Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R
    Ann N Y Acad Sci. 1993 Aug 12; 690:385-7.; 
    PubMed
  40. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R
    N Engl J Med. 1992 Oct 22; 327(17):1209-15.; 
    PubMed
  41. Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction.
    Kwak LW, Campbell MJ, Levy R
    Cancer Res. 1992 Aug 01; 52(15):4117-20.; 
    PubMed
  42. Interleukin 3 is a growth factor for human follicular B cell lymphoma.
    Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Levy R, Krensky AM
    J Exp Med. 1992 Feb 01; 175(2):371-6.; 
    PubMed
  43. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.
    Campbell MJ, Zelenetz AD, Levy S, Levy R
    Mol Immunol. 1992 Feb; 29(2):193-203.; 
    PubMed
  44. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy.
    Kwak LW, Campbell MJ, Zelenetz AD, Levy R
    Blood. 1991 Nov 15; 78(10):2768-72.; 
    PubMed
  45. Ig VH gene expression among human follicular lymphomas.
    Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R
    Blood. 1991 Sep 15; 78(6):1561-8.; 
    PubMed
  46. Follicular lymphoma: a model of lymphoid tumor progression in man.
    Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S
    Ann Oncol. 1991 Feb; 2 Suppl 2:115-22.; 
    PubMed
  47. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW, Campbell M, Levy R
    Cancer Detect Prev. 1991; 15(4):323-5.; 
    PubMed
  48. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.
    Kwak LW, Campbell MJ, Zelenetz AD, Levy R
    Blood. 1990 Dec 01; 76(11):2411-7.; 
    PubMed
  49. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R
    J Immunol. 1990 Aug 01; 145(3):1029-36.; 
    PubMed
  50. Idiotypic variation in a human B lymphoma cell line.
    Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S, Levy R
    J Immunol. 1990 Jan 15; 144(2):752-8.; 
    PubMed
  51. Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V kappa genes to downstream J kappa segment in a murine B cell line.
    Levy S, Campbell MJ, Levy R
    J Exp Med. 1989 Jul 01; 170(1):1-13.; 
    PubMed
  52. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R
    Int Rev Immunol. 1989; 4(4):251-70.; 
    PubMed
  53. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
    Campbell MJ, Esserman L, Levy R
    J Immunol. 1988 Nov 01; 141(9):3227-33.; 
    PubMed
  54. Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.
    Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC
    J Immunol. 1988 Oct 15; 141(8):2855-60.; 
    PubMed
  55. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.
    Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R
    J Immunol. 1988 Jul 01; 141(1):333-9.; 
    PubMed
  56. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
    Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R
    J Immunol. 1987 Oct 15; 139(8):2825-33.; 
    PubMed
  57. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses.
    Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R
    Blood. 1987 Jan; 69(1):199-210.; 
    PubMed
  58. Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies.
    Campbell M, Bieber M, Levy R, Teng NN
    J Immunol. 1986 Apr 15; 136(8):2983-8.; 
    PubMed
  59. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
    Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R
    J Immunol. 1986 Feb 01; 136(3):1123-30.; 
    PubMed